排序方式: 共有4条查询结果,搜索用时 0 毫秒
1
1.
The title compound was synthesized by the reaction of 4-tert-butyl-5-(4-chlorobenzyl)-2-aminothiazole with 2,6-difluorobenzoic acid. The crystal structure of the title compound, C21H19ClF2N2OS, was determined by single-crystal X-ray diffraction. The crystal belongs to the triclinic system, space group Pbca with a = 12.6479(13), b = 13.1204(13), c = 14.1341(15), Z = 4, V = 2011.5(4)3, Mr = 420.89, Dc = 1.390 g/cm3, S = 1.023, μ = 0.326 mm-1, F(000) = 872, the final R = 0.0365 and wR = 0.0880 for 6101 observed reflections(I 2σ(I)), and R = 0.0507, wR = 0.0978 for 7779 independent reflections. X-ray crystal structure displays that the hydrogen bonding interactions observed link the molecules to form a dimeric unit. The preliminary biological test of the title compound shows good antitumor activity, with IC50 of 0.046 μmol/mL against the Hela cell line. 相似文献
2.
以芳香胺和4,4-二甲基-1-芳基-2-溴戊-3-酮为原料, 设计合成了29种新的5-苄基-4-叔丁基-2-芳氨基噻唑氢溴酸盐化合物; 其结构经1H NMR和元素分析等确证. 体外抗肿瘤活性测试结果表明, 化合物A4, A5, A12和A29对人非小细胞肺癌细胞A549的IC50值分别为0.016, 0.019, 0.019和0.026 μmol/mL, 与阳性对照物紫杉醇(IC50值为0.022 μmol/mL)相当; 化合物A5, A7, A13, A14和A19对肝癌细胞Bel7402的IC50值分别为0.021, 0.021, 0.026, 0.014和0.029 μmol/mL, 与阳性对照物紫杉醇的IC50值(0.030 μmol/mL)相近. 利用倒置显微镜和Hoechst33342-PI双染色法观察了细胞经化合物处理后的形态变化. 相似文献
3.
4.
1